Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IcCisBole

ABSTRACT: Cis boleti

PROVIDER: PRJEB71254 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12370404.fastq.gz	Fastqsanger.gz
	ERR12374380_1.fastq.gz	Fastqsanger.gz
	ERR12374380_2.fastq.gz	Fastqsanger.gz
	ERR14365000_1.fastq.gz	Fastqsanger.gz
	ERR14365000_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 5

Similar Datasets

Cis boleti

Project description:Cis boleti overview

| PRJNA1053443 | ENA

icCisBole

Project description:Cis boleti, genomic and transcriptomic data

| PRJEB71253 | ENA

icDiaBole

Project description:Diaperis boleti

| PRJEB66249 | ENA

Diaperis boleti

Project description:Diaperis boleti overview

| PRJNA1036351 | ENA

icDiaBole1

Project description:Diaperis boleti genome assembly, icDiaBole1

| PRJEB68176 | ENA

icDiaBole

Project description:Diaperis boleti, genomic and transcriptomic data

| PRJEB66248 | ENA

icDiaBole1 alternate haplotype

Project description:Diaperis boleti genome assembly, icDiaBole1, alternate haplotype

| PRJEB68177 | ENA

Therapeutic Potential of Eleutheroside E:Alleviates Cisplatin-Induced ototoxicity, inhibiting cochlear cells pyroptosis by down-regulating MAPK/ NF-κB /NLRP3 Signalling Pathway

Project description:As one of the widely-used broad-spectrum anti-cancer drug, ototoxicity occurrence limited the usage of Cisplatin in clinical practice. At the same time, Eleutheroside E are found with kindny and never protection. However, the mechanism of the protection is remained unclear. In this study, 27 C57BL/6J mice were used and divided into Ctrl group with normal Saline injected, Cis and Cis + EE group with injection of Cis and Cis + EE peritoneally for Cisplatin-reduced ototoxicity modelling and intervention, then cochlears were dissected for proteomics. Network pharmacology to predict the target and biological mechanism of Eleutheroside E against cisplatin ototoxicity and Eleutheroside E might play an antagonistic role through the regulation of MAPK and pyrogenic signaling pathway. Compare with Cis group, Cis+EE group mice have a lower threshold value in ABR result and the group shows less cell pyroptosis than Cis group. Morphology results also indicated that Cis+EE group reduced space of spiral ganglion and the vascular structure was relatively clear than the Cis group. In addition, compared with Cis group, mRNA expression of NLRP3, GSDMD, ASC, Caspase-1, IL-1β and IL-18 genes in Cis+EE group decreased. The expression of p-JNK, p-ERK, P-P38, NF-κB P65, Cleaved Caspase-1, GSDMD was decreased, and the expression of IκB was increased. This study demonstrated that Eleutheroside E exerts an antagonistic effect on Cisplatin ototoxicity by down-regulating the activity of MAPK/NF-κB/NLRP3 signaling pathway, reducing the expression level of pyroptosis related proteins and inflammatory factors after cisplatin administration, and then inhibiting pyroptosis.

2023-11-16 | PXD047048 |

Proteogenomics of urothelial bladder cancer progression reveals the distinguished molecular features of different pathological subtypes

Project description:We reported a comprehensive proteogenomics analysis, including whole-genome sequencing, RNA sequencing, and proteomics and phosphoproteomics profiling, of 448 trace-tumor-samples from 190 urothelial bladder neoplasm patients, covering the whole spectrum of disease stages and grades. DNA damage was a key signaling pathway in the progression of carcinoma in situ (CIS) and related to APOBEC signature. Proteogenomic integration analysis indicated the mutation of HRAS regulated mTOR signaling to form urothelial papilloma rather than papillary urothelial cancer (PUC). Glucolipid metabolism increase and lower immune cell infiltration were significantly associated with PUC compared to CIS. Proteomic analysis distinguished the origins of invasive tumors (PUC-derived and CIS-derived), related to distinct clinical prognosis and molecular features. Additionally, loss of RBPMS, associated with CIS-derived tumors, was validated to increase the activity of SMAD-bound JUN and promote metastasis.

2023-08-02 | PXD043775 |

icCisBila

Project description:Cis bilamellatus

| PRJEB76355 | ENA